Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model

Prostate

Volumn 62, Issue 4, 2005, Pages 322-338

  Johnson, Mac A ^a,b   Iversen, Philip ^a   Schwier, Phillip ^a   Corn, Angela L ^a   Sandusky, George ^a   Graff, Jeremy ^a   Neubauer, Blake Lee ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Cancer; Castration; Mouse; Prostate; Transgenic

Indexed keywords

ANDROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; LESIONS AND DEFECTS; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TRANSGENIC MOUSE; TUMOR GROWTH;

ANDROGENS; ANIMALS; CASTRATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 13544258983     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20148     Document Type: Article

References (41)

1. Jackson-Grusby L. Modeling cancer in mice. Oncogene 2002;21:5504-5514.
2. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
3. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis Mar 1999;2:70-75.
4. Gingrich JR, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
5. Efron B. CBMS monograph No. 38. Philadelphia, PA: SIAM, 1982.
6. Kaplan-Lefko P, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. The Prostate 2003;55:219-237.
7. Greenberg NM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-239.
8. Gingrich JR, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-4691.
9. Huggins C, Stevens RE, Hodges C. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Arch Surg 1941;43:209-223.
10. Catalona WJ, Scott WW. Carcinoma of the prostate: A review. J Urol 1978;119:1-8.
11. Hayward SW, Cunha GR. The prostate: Development and physiology. Radiol Clin North Am 2000;38:1-14.
12. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61:5038-5044.
13. Cunha GR, Lung B. The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exper Zool 1978;205:181-193.
14. Hayward SW, Del Buono R, Deshpande N, Hall PA. A functional model of adult human prostate epithelium. The role of androgens and stroma in architectural organisation and the maintenance of differentiated secretory function. J Cell Sci 1992;102:361-372.
15. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocrine-Related Cancer 2002;9:61-73.
16. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106.
17. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North America 1999;26:263-273.
18. Vest SA, Frazier TH. Survival following castration for prostate cancer. J Urol 1946;56:97.
19. Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1818 cases. J Am Med Assoc 1950;143:1317.
20. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982;128:335-340.
21. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison. J Urol 1999;161:1223-1227; 1227-1228 (discussion).
22. Grimm MO, et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2002;41:628-634; 634 (discussion).
23. Zincke H, Utz DC, Thule PM, Taylor WF. Treatment options for patients with stage D1 (T0-3,N1-2,M0) adenocarcinoma of prostate. Urology 1987;30:307-315.
24. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: Prognostic variables and outcome. J Urol 1994;151:1330-1333.
25. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002;168:1008-1012.
26. Frohmuller HG, Theiss M, Manseck A, Wirth MP. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 1995;27:202-206.
27. Sakr WA, Ward C, Grignon DJ, Haas GP. Epidemiology and molecular biology of early prostatic neoplasia. Mol Urol 2000;4:109-113; 115 (discussion).
28. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001 [erratum appears in CA Cancer J Clin 2001 Mar-Apr;51(2):144]. CA Cancer J Clin 2001;51:15-36.
29. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002;3:364-373.
30. Konety BR, Getzenberg RH. Vitamin D and prostate cancer. Urol Clin North America 2002;29:95-106.
31. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-746.
32. Zhang PL, et al. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-182.
33. Chen SS, et al. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002;89:710-713.
34. Furuya Y, Nozaki T, Nagakawa O, Fuse H. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocr J 2002;49:85-90.
35. Imamoto T, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573-578.
36. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20:605-608.
37. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-482.
38. Miller LR, et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-453.
39. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, For LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
40. Schatzl G, et al. Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate 2000;44:219-224.
41. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.